Last reviewed · How we verify
Anticholinergic Deprescription
Anticholinergic deprescription is a clinical practice of systematically reducing or discontinuing anticholinergic medications to minimize cognitive and physical adverse effects.
Anticholinergic deprescription is a clinical practice of systematically reducing or discontinuing anticholinergic medications to minimize cognitive and physical adverse effects. Used for Reduction of anticholinergic medication burden in patients taking multiple anticholinergic agents, Prevention of cognitive decline and delirium in older adults, Reduction of fall risk in elderly patients.
At a glance
| Generic name | Anticholinergic Deprescription |
|---|---|
| Sponsor | Deepak K. Sarpal, M.D. |
| Modality | Small molecule |
| Therapeutic area | Geriatrics / Deprescribing / Polypharmacy Management |
| Phase | FDA-approved |
Mechanism of action
This is not a drug itself, but rather a deprescribing strategy that involves the gradual withdrawal of anticholinergic agents (medications that block acetylcholine receptors) from patients' regimens. Anticholinergics are associated with increased risk of cognitive impairment, falls, and other adverse effects, particularly in older adults. Deprescription aims to improve patient outcomes by eliminating unnecessary anticholinergic burden while managing underlying conditions through alternative therapies.
Approved indications
- Reduction of anticholinergic medication burden in patients taking multiple anticholinergic agents
- Prevention of cognitive decline and delirium in older adults
- Reduction of fall risk in elderly patients
Common side effects
Key clinical trials
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders (NA)
- Medication Empowerment and Deprescription for Safety (MEDS) Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anticholinergic Deprescription CI brief — competitive landscape report
- Anticholinergic Deprescription updates RSS · CI watch RSS
- Deepak K. Sarpal, M.D. portfolio CI